The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
Open accessThe DOI matches its Crossref record; 446 of the 448 references it cites were found in a registry or an index.
Abstract
Therapeutic approaches that lower circulating low-density lipoprotein (LDL)-cholesterol significantly reduced the burden of cardiovascular disease over the last decades. However, the persistent rise in the obesity epidemic is beginning to reverse this decline. Alongside obesity, the incidence of nonalcoholic fatty liver disease (NAFLD) has substantially increased in the last three decades. Currently, approximately one third of world population is affected by NAFLD. Notably, the presence of NAFLD and particularly its more severe form, nonalcoholic steatohepatitis (NASH), serves as an independent risk factor for atherosclerotic cardiovascular disease (ASCVD), thus, raising interest in the relationship between these two diseases. Importantly, ASCVD is the major cause of death in patients with NASH independent of traditional risk factors. Nevertheless, the pathophysiology linking NAFLD/NASH with ASCVD remains poorly understood. While dyslipidemia is a common risk factor underlying both diseases, therapies that lower circulating LDL-cholesterol are largely ineffective against NASH. While there are no approved pharmacological therapies for NASH, some of the most advanced drug candidates exacerbate atherogenic dyslipidemia, raising concerns regarding their adverse cardiovascular consequences. In this review, we address current gaps in our understanding of the mechanisms linking NAFLD/NASH and ASCVD, explore strategies to simultaneously model these diseases, evaluate emerging biomarkers that may be useful to diagnose the presence of both diseases, and discuss investigational approaches and ongoing clinical trials that potentially target both diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“fibrotic MASH is an independent risk factor for atherosclerotic cardiovascular disease, which is the leading cause of death in people with MASH (56).”
From Impaired TIM4-mediated efferocytosis by liver macrophages contributes to fibrosis in metabolic dysfunction–associated steatohepatitis (2025) · cites this paper as [56]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–400 of 446
Hepatokines and metabolism: Deciphering communication from the liver
Jensen-Cody, S. O., & Potthoff, M. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101138 · Cited by 252
The sodium/glucose cotransport family SLC5
Turk, E., & Wright, E. M. (2004) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/s00424-003-1063-6 · Cited by 251
Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis
Zhu, C., Kim, K., Wang, X., Bartolome, A., Salomao, M., Dongiovanni, P., Meroni, M., Graham, M. J., Yates, K. P., Diehl, A. M., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat0344 · Cited by 250 · cited 2×
“Consistently, hepatocyte-specific inactivation of Notch signaling protects mice from developing NASH-induced hepatic fibrosis (69).”
BackgroundThe Sweet Path to Metabolic Demise: Fructose and Lipid Synthesis
Herman, M. A., & Samuel, V. T. (2016) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.06.005 · Cited by 247
Snodgrass, R. G., Huang, S., Choi, I.-W., Rutledge, J. C., & Hwang, D. H. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300298 · Cited by 243
US life expectancy stalls due to cardiovascular disease, not drug deaths
Mehta, N. K., Abrams, L. R., & Myrskylä, M. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1920391117 · Cited by 240 · cited 2×
“More troubling is the recent trend that life expectancy growth has begun to decline, with a substantial rise in CVD deaths having the most impact (29).”
BackgroundNelson, A., Torres, D. M., Morgan, A. E., Fincke, C., & Harrison, S. A. (2009) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31819c392e · Cited by 230
Softic, S., Meyer, J. G., Wang, G.-X., Gupta, M. K., Batista, T. M., Lauritzen, H. P. M. M., Fujisaka, S., Serra, D., Herrero, L., Willoughby, J., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.09.003 · Cited by 227
Dietary cholesterol and atherosclerosis
McNamara, D. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(00)00156-6 · Cited by 223 · cited 1×
“Since conventional atherogenic diets parallel human consumption of cholesterol (96, 97), but typically contain approximately one-tenth that of murine NASH diets (0.”
BackgroundRatziu, V., de Guevara, L., Safadi, R., Poordad, F., Fuster, F., Flores-Figueroa, J., Arrese, M., Fracanzani, A. L., Ben Bashat, D., Lackner, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01495-3 · Cited by 222
Everett, B. M., MacFadyen, J. G., Thuren, T., Libby, P., Glynn, R. J., & Ridker, P. M. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.08.011 · Cited by 220
Loomba, R., Mohseni, R., Lucas, K. J., Gutierrez, J. A., Perry, R. G., Trotter, J. F., Rahimi, R. S., Harrison, S. A., Ajmera, V., Wayne, J. D., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.07.025 · Cited by 220
Calle, R. A., Amin, N. B., Carvajal-Gonzalez, S., Ross, T. T., Bergman, A., Aggarwal, S., Crowley, C., Rinaldi, A., Mancuso, J., Aggarwal, N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01489-1 · Cited by 219
High-Sensitivity C-Reactive Protein as Cardiovascular Risk Marker in Patients with Diabetes Mellitus
Pfützner, A., & Forst, T. (2006) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2006.8.28 · Cited by 217
Lawitz, E. J., Coste, A., Poordad, F., Alkhouri, N., Loo, N., McColgan, B. J., Tarrant, J. M., Nguyen, T., Han, L., Chung, C., et al. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.04.042 · Cited by 217
Bergmark, B. A., Marston, N. A., Bramson, C. R., Curto, M., Ramos, V., Jevne, A., Kuder, J. F., Park, J.-G., Murphy, S. A., Verma, S., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.059266 · Cited by 216
Nakajima, A., Eguchi, Y., Yoneda, M., Imajo, K., Tamaki, N., Suganami, H., Nojima, T., Tanigawa, R., Iizuka, M., Iida, Y., et al. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16596 · Cited by 213
Nutritional model of steatohepatitis and metabolic syndrome in the Ossabaw miniature swine #
Lee, L., Alloosh, M., Saxena, R., Van Alstine, W., Watkins, B. A., Klaunig, J. E., Sturek, M., & Chalasani, N. (2009) · Hepatology · doi:10.1002/hep.22904 · Cited by 211
Ceramide as a Mediator of Non-Alcoholic Fatty Liver Disease and Associated Atherosclerosis
Kasumov, T., Li, L., Li, M., Gulshan, K., Kirwan, J. P., Liu, X., Previs, S., Willard, B., Smith, J. D., & McCullough, A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126910 · Cited by 209
Reinehr, T., & Roth, C. L. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1505 · Cited by 208
Cholesterol Stabilizes TAZ in Hepatocytes to Promote Experimental Non-alcoholic Steatohepatitis
Wang, X., Cai, B., Yang, X., Sonubi, O. O., Zheng, Z., Ramakrishnan, R., Shi, H., Valenti, L., Pajvani, U. B., Sandhu, J., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.03.010 · Cited by 204
Self-citationAn Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease
Pei, K., Gui, T., Kan, D., Feng, H., Jin, Y., Yang, Y., Zhang, Q., Du, Z., Gai, Z., Wu, J., et al. (2020) · BioMed Research International · doi:10.1155/2020/4020249 · Cited by 204
Leveraging Human Genetics to Identify Potential New Treatments for Fatty Liver Disease
Romeo, S., Sanyal, A., & Valenti, L. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.12.002 · Cited by 202
Lowe, G. D. O., Yarnell, J. W. G., Rumley, A., Bainton, D., & Sweetnam, P. M. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.21.4.603 · Cited by 199
Bril, F., Kalavalapalli, S., Clark, V. C., Lomonaco, R., Soldevila-Pico, C., Liu, I.-C., Orsak, B., Tio, F., & Cusi, K. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.12.001 · Cited by 199
Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia
Morrow, M. R., Batchuluun, B., Wu, J., Ahmadi, E., Leroux, J. M., Mohammadi-Shemirani, P., Desjardins, E. M., Wang, Z., Tsakiridis, E. E., Lavoie, D. C. T., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.05.004 · Cited by 199
Liao, H.-W., Saver, J. L., Wu, Y.-L., Chen, T.-H., Lee, M., & Ovbiagele, B. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-013927 · Cited by 198
Raubenheimer, P. J., Nyirenda, M. J., & Walker, B. R. (2006) · Diabetes · doi:10.2337/db06-0097 · Cited by 197 · cited 1×
“While enhancing liver fat accumulation, the cholinedeficient high-fat diet actually attenuates fasting plasma insulin and improves glucose tolerance (120).”
BackgroundIncreased serum FGF21 levels in patients with nonalcoholic fatty liver disease
Yilmaz, Y., Eren, F., Yonal, O., Kurt, R., Aktas, B., Celikel, C. A., Ozdogan, O., Imeryuz, N., Kalayci, C., & Avsar, E. (2010) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02338.x · Cited by 195
Chow, W. S., Xu, A., Woo, Y. C., Tso, A. W. K., Cheung, S. C. W., Fong, C. H. Y., Tse, H. F., Chau, M. T., Cheung, B. M. Y., & Lam, K. S. L. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.301599 · Cited by 193
C57BL/6 mice fed high fat diets as models for diabetes-accelerated atherosclerosis
Schreyer, S. A., Wilson, D. L., & LeBoeuf, R. C. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(97)00165-2 · Cited by 192
Lai, L.-L., Vethakkan, S. R., Nik Mustapha, N. R., Mahadeva, S., & Chan, W.-K. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-5477-1 · Cited by 191
Duez, H., Chao, Y.-S., Hernandez, M., Torpier, G., Poulain, P., Mundt, S., Mallat, Z., Teissier, E., Burton, C. A., Tedgui, A., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206966200 · Cited by 186
Kathirvel, E., Morgan, K., Nandgiri, G., Sandoval, B. C., Caudill, M. A., Bottiglieri, T., French, S. W., & Morgan, T. R. (2010) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00249.2010 · Cited by 186
Gilbert, J., Lekstrom-Himes, J., Donaldson, D., Lee, Y., Hu, M., Xu, J., Wyant, T., & Davidson, M. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.11.005 · Cited by 185
Hoekstra, M., Kruijt, J. K., Van Eck, M., & van Berkel, T. J. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301189200 · Cited by 183
Hanniman, E. A., Lambert, G., McCarthy, T. C., & Sinal, C. J. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m500390-jlr200 · Cited by 179
Schierwagen, R., Maybüchen, L., Zimmer, S., Hittatiya, K., Bäck, C., Klein, S., Uschner, F. E., Reul, W., Boor, P., Nickenig, G., et al. (2015) · Scientific Reports · doi:10.1038/srep12931 · Cited by 179 · cited 1×
“mice, demonstrating significant fibrosis and hepatocellular ballooning in Western diet-fed mice after just 7 weeks (90).”
BackgroundOre, A., & Akinloye, O. (2019) · Medicina · doi:10.3390/medicina55020026 · Cited by 179
Mathews, S. (2000) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(00)00237-9 · Cited by 178
Mardinoglu, A., Bjornson, E., Zhang, C., Klevstig, M., Söderlund, S., Ståhlman, M., Adiels, M., Hakkarainen, A., Lundbom, N., Kilicarslan, M., et al. (2017) · Molecular Systems Biology · doi:10.15252/msb.20167422 · Cited by 176
Zhang, F., Zhao, S., Yan, W., Xia, Y., Chen, X., Wang, W., Zhang, J., Gao, C., Peng, C., Yan, F., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.10.013 · Cited by 175
Ampomah, P. B., Cai, B., Sukka, S. R., Gerlach, B. D., Yurdagul, A., Wang, X., Kuriakose, G., Darville, L. N. F., Sun, Y., Sidoli, S., et al. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00551-7 · Cited by 173
Self-citationMitsuyoshi, H., Yasui, K., Harano, Y., Endo, M., Tsuji, K., Minami, M., Itoh, Y., Okanoue, T., & Yoshikawa, T. (2009) · Hepatology Research · doi:10.1111/j.1872-034x.2008.00464.x · Cited by 172 · cited 2×
“Consequently, circulating free fatty acids increase and are then taken up by secondary storage organs, particularly the liver, Frontiers in Cardiovascular Medicine 04 through fatty acid transport protein 5 (FATP5) and the scavenger receptor CD36 (52, 53).”
BackgroundPrimary hyperoxalurias: Disorders of glyoxylate detoxification
Salido, E., Pey, A. L., Rodriguez, R., & Lorenzo, V. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.03.004 · Cited by 171
Bril, F., Lomonaco, R., Orsak, B., Ortiz-Lopez, C., Webb, A., Tio, F., Hecht, J., & Cusi, K. (2014) · Hepatology · doi:10.1002/hep.26988 · Cited by 171
Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis
Jian, C., Fu, J., Cheng, X., Shen, L.-J., Ji, Y.-X., Wang, X., Pan, S., Tian, H., Tian, S., Liao, R., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.04.011 · Cited by 171
Circadian Clock Control by Polyamine Levels through a Mechanism that Declines with Age
Zwighaft, Z., Aviram, R., Shalev, M., Rousso-Noori, L., Kraut‐Cohen, J., Golik, M., Brandis, A. S., Reinke, H., Aharoni, A., Kahana, C., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.09.011 · Cited by 170
Brown, J. M., Chung, S., Sawyer, J. K., Degirolamo, C., Alger, H. M., Nguyen, T., Zhu, X., Duong, M.-N., Wibley, A. L., Shah, R., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.793182 · Cited by 170
Identification of a mammalian angiopoietin-related protein expressed specifically in liver
Conklin, D., Gilbertson, D., Taft, D. W., Maurer, M. F., Whitmore, T. E., Smith, D. L., Walker, K. M., Chen, L. H., Wattler, S., Nehls, M., et al. (1999) · Genomics · doi:10.1006/geno.1999.6041 · Cited by 169
Minicocci, I., Montali, A., Robciuc, M. R., Quagliarini, F., Censi, V., Labbadia, G., Gabiati, C., Pigna, G., Sepe, M. L., Pannozzo, F., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1298 · Cited by 168
Anti-TNF in rheumatoid arthritis: an overview
Radner, H., & Aletaha, D. (2015) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-015-0344-y · Cited by 163
Barbuio, R., Milanski, M., Bertolo, M. B., Saad, M. J., & Velloso, L. A. (2007) · Journal of Endocrinology · doi:10.1677/joe-07-0234 · Cited by 163
Park, H.-S., Jang, J. E., Ko, M. S., Woo, S. H., Kim, B. J., Kim, H. S., Park, H. S., Park, I.-S., Koh, E. H., & Lee, K.-U. (2016) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2016.40.5.376 · Cited by 160
Inhibition of nonalcoholic fatty liver disease in mice by selective inhibition of mTORC1
Gosis, B. S., Wada, S., Thorsheim, C., Li, K., Jung, S., Rhoades, J. H., Yang, Y., Brandimarto, J., Li, L., Uehara, K., et al. (2022) · Science · doi:10.1126/science.abf8271 · Cited by 159
Wurtz, P., Raiko, J. R., Magnussen, C. G., Soininen, P., Kangas, A. J., Tynkkynen, T., Thomson, R., Laatikainen, R., Savolainen, M. J., Laurikka, J., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs020 · Cited by 158
Mizoguchi, M., Tahara, N., Tahara, A., Nitta, Y., Kodama, N., Oba, T., Mawatari, K., Yasukawa, H., Kaida, H., Ishibashi, M., et al. (2011) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2011.08.007 · Cited by 156
Liu, Z., Ma, X., Ilyas, I., Zheng, X., Luo, S., Little, P. J., Kamato, D., Sahebkar, A., Wu, W., Weng, J., et al. (2021) · Theranostics · doi:10.7150/thno.54498 · Cited by 155
Zhenyukh, O., González‐Amor, M., Rodrigues‐Diez, R. R., Esteban, V., Ruiz‐Ortega, M., Salaices, M., Mas, S., Briones, A. M., & Egido, J. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13759 · Cited by 154
Assessing the causal association of glycine with risk of cardio-metabolic diseases
Wittemans, L. B. L., Lotta, L. A., Oliver‐Williams, C., Stewart, I. D., Surendran, P., Karthikeyan, S., Day, F. R., Koulman, A., Imamura, F., Zeng, L., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08936-1 · Cited by 150
Loomba, R., & Adams, L. A. (2019) · Hepatology · doi:10.1002/hep.30946 · Cited by 150
Marchesini, G., & Marzocchi, R. (2007) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.02.013 · Cited by 149 · cited 5×
“strongly associated with the metabolic syndrome (3), which currently afflicts approximately 90% of obese patients (4) and approximately 55% of individuals with type 2 diabetes (T2D) (5).”
BackgroundInfluentialAnroedh, S., Hilvo, M., Akkerhuis, K. M., Kauhanen, D., Koistinen, K., Oemrawsingh, R., Serruys, P., van Geuns, R.-J., Boersma, E., Laaksonen, R., et al. (2018) · Journal of Lipid Research · doi:10.1194/jlr.p081281 · Cited by 149
Esquejo, R. M., Salatto, C. T., Delmore, J., Albuquerque, B., Reyes, A., Shi, Y., Moccia, R., Cokorinos, E., Peloquin, M., Monetti, M., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.04.009 · Cited by 147
Regulation of tumour necrosis factor-alpha release from human adipose tissue in vitro
Sewter, C., Digby, J., Blows, F., Prins, J., & O'Rahilly, S. (1999) · Journal of Endocrinology · doi:10.1677/joe.0.1630033 · Cited by 146
Simon, J., Nuñez-García, M., Fernández-Tussy, P., Barbier-Torres, L., Fernández-Ramos, D., Gómez-Santos, B., Buqué, X., Lopitz-Otsoa, F., Goikoetxea-Usandizaga, N., Serrano-Macia, M., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.01.013 · Cited by 146
Sanderson, L. M., Boekschoten, M. V., Desvergne, B., Müller, M., & Kersten, S. (2010) · Physiological Genomics · doi:10.1152/physiolgenomics.00127.2009 · Cited by 145
Bhattacharya, S., Granger, C. B., Craig, D., Haynes, C., Bain, J., Stevens, R. D., Hauser, E. R., Newgard, C. B., Kraus, W. E., Newby, L. K., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.10.036 · Cited by 145
Sugiyama, T., Tsugawa, Y., Tseng, C.-H., Kobayashi, Y., & Shapiro, M. F. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.1927 · Cited by 144
Crosstalk Between Macrophages and Vascular Smooth Muscle Cells in Atherosclerotic Plaque Stability
Yurdagul, A. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.316233 · Cited by 144
Self-citationGordon, S. M., Li, H., Zhu, X., Shah, A. S., Lu, L. J., & Davidson, W. S. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00213 · Cited by 141
Manjunath, C. N., Rawal, J. R., Irani, P. M., & Madhu, K. (2013) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.122600 · Cited by 141
Hepatocyte-specific deletion of Pparα promotes NAFLD in the context of obesity
Régnier, M., Polizzi, A., Smati, S., Lukowicz, C., Fougerat, A., Lippi, Y., Fouché, E., Lasserre, F., Naylies, C., Bétoulières, C., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-63579-3 · Cited by 140
Koca, S. S., Bahcecioglu, I. H., Poyrazoglu, O. K., Ozercan, I. H., Sahin, K., & Ustundag, B. (2008) · Inflammation · doi:10.1007/s10753-007-9053-z · Cited by 135
Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease
Shen, Y., Ma, X., Zhou, J., Pan, X., Hao, Y., Zhou, M., Lu, Z., Gao, M., Bao, Y., & Jia, W. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-124 · Cited by 135
Rizzo, M., Rizvi, A. A., Patti, A. M., Nikolic, D., Giglio, R. V., Castellino, G., Li Volti, G., Caprio, M., Montalto, G., Provenzano, V., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0480-8 · Cited by 135
mTORC1 activates SREBP-2 by suppressing cholesterol trafficking to lysosomes in mammalian cells
Eid, W., Dauner, K., Courtney, K. C., Gagnon, A., Parks, R. J., Sorisky, A., & Zha, X. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705304114 · Cited by 135
Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis
Siddiqui, M. S., Van Natta, M. L., Connelly, M. A., Vuppalanchi, R., Neuschwander-Tetri, B. A., Tonascia, J., Guy, C., Loomba, R., Dasarathy, S., Wattacheril, J., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.006 · Cited by 135 · cited 4×
“Since these studies terminated at 72 weeks (21), the long-term effects of obetacholic acid on atherosclerosis remain unknown.”
BackgroundInfluentialFatty liver is an independent predictor of early carotid atherosclerosis
Pais, R., Giral, P., Khan, J.-F., Rosenbaum, D. H., Housset, C., Poynard, T., & Ratziu, V. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.02.023 · Cited by 134 · cited 1×
“Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas.”
BackgroundWhy Do Men Accumulate Abdominal Visceral Fat?
Nauli, A. M., & Matin, S. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.01486 · Cited by 132
DIETARY CHOLESTEROL AND ISCHAEMIC HEART DISEASE
Shekelle, R. B., & Stamler, J. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92759-1 · Cited by 131 · cited 1×
“Since conventional atherogenic diets parallel human consumption of cholesterol (96, 97), but typically contain approximately one-tenth that of murine NASH diets (0.”
BackgroundGoettsch, C., Hutcheson, J. D., Hagita, S., Rogers, M. A., Creager, M. D., Pham, T., Choi, J., Mlynarchik, A. K., Pieper, B., Kjolby, M., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.06.011 · Cited by 131
Honda, Y., Kessoku, T., Ogawa, Y., Tomeno, W., Imajo, K., Fujita, K., Yoneda, M., Takizawa, T., Saito, S., Nagashima, Y., et al. (2017) · Scientific Reports · doi:10.1038/srep42477 · Cited by 131
Ermer, T., Nazzal, L., Tio, M. C., Waikar, S. S., Aronson, P. S., & Knauf, F. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00643-3 · Cited by 131
Davidson, M., Meyer, P. M., Haffner, S., Feinstein, S., D’Agostino, R., Kondos, G. T., Perez, A., Chen, Z., & Mazzone, T. (2008) · Circulation · doi:10.1161/circulationaha.107.746610 · Cited by 128
Johari, M. I., Yusoff, K., Haron, J., Nadarajan, C., Ibrahim, K. N., Wong, M. S., Hafidz, M. I. A., Chua, B. E., Hamid, N., Arifin, W. N., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-47763-8 · Cited by 128
Auge, N., Garcia, V., Maupas-Schwalm, F., Levade, T., Salvayre, R., & Negre-Salvayre, A. (2002) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000043453.21629.3b · Cited by 125
Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug
Nesti, L., Tricò, D., Mengozzi, A., & Natali, A. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01294-7 · Cited by 124
PARK, T., Rosebury, W. S., Kindt, E. K., Kowala, M. C., & Panek, R. L. (2008) · Pharmacological Research · doi:10.1016/j.phrs.2008.06.005 · Cited by 123
Contribution of Dietary Oxalate and Oxalate Precursors to Urinary Oxalate Excretion
Crivelli, J. J., Mitchell, T., Knight, J. L., Wood, K. D., Assimos, D. G., Holmes, R. P., & Fargue, S. (2020) · Nutrients · doi:10.3390/nu13010062 · Cited by 123
Jiang, M., Li, C., Liu, Q., Wang, A., & Lei, M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00665 · Cited by 122
Zhang, Y., Qiu, J., Wang, X., Zhang, Y., & Xia, M. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.237453 · Cited by 121
Sandhya, N., Gokulakrishnan, K., Rangasamy, S., Syed, F., Ravikumar, R., Mohan, V., & Balasubramanyam, M. (2010) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2010.04.003 · Cited by 118
THE BIOSYNTHESIS AND TURNOVER OF OXALATE IN NORMAL AND HYPEROXALURIC SUBJECTS *
Elder, T., & Wyngaarden, J. Β. (1960) · Journal of Clinical Investigation · doi:10.1172/jci104151 · Cited by 118
Ding, Y., Svingen, G. F. T., Pedersen, E. R., Gregory, J. F., Ueland, P. M., Tell, G. S., & Nygard, O. K. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002621 · Cited by 118
Honda, T., Ishigami, M., Luo, F., Lingyun, M., Ishizu, Y., Kuzuya, T., Hayashi, K., Nakano, I., Ishikawa, T., Feng, G., et al. (2017) · Metabolism · doi:10.1016/j.metabol.2016.12.013 · Cited by 118
Chung, S. I., Moon, H., Ju, H.-L., Cho, K. J., Kim, D. Y., Han, K.-H., Eun, J. W., Nam, S. W., Ribback, S., Dombrowski, F., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.10.007 · Cited by 117 · cited 1×
“In addition, Sonic Hedgehog and Indian Hedgehog activates hepatic stellate cells and drive ECM protein synthesis (71).”
BackgroundHe, J., Lee, J. H., Febbraio, M., & Xie, W. (2011) · Experimental Biology and Medicine · doi:10.1258/ebm.2011.011128 · Cited by 116 · cited 2×
“Consequently, circulating free fatty acids increase and are then taken up by secondary storage organs, particularly the liver, Frontiers in Cardiovascular Medicine 04 through fatty acid transport protein 5 (FATP5) and the scavenger receptor CD36 (52, 53).”
BackgroundDietary fructose induces endotoxemia and hepatic injury in calorically controlled primates
Kavanagh, K., Wylie, A. T., Tucker, K. L., Hamp, T. J., Gharaibeh, R. Z., Fodor, A. A., & Cullen, J. M. (2013) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.112.057331 · Cited by 116 · cited 1×
“In the gastrointestinal tract, fructose deteriorates the gut barrier and promotes chronic inflammation by endotoxemia (110).”
BackgroundSaponaro, C., Sabatini, S., Gaggini, M., Carli, F., Rosso, C., Positano, V., Armandi, A., Caviglia, G. P., Faletti, R., Bugianesi, E., et al. (2022) · Liver International · doi:10.1111/liv.15377 · Cited by 116
Lee, J. H., Kang, Y. E., Chang, J. Y., Park, K. C., Kim, H.-W., Kim, J. T., Kim, H. J., Yi, H., Shong, M., Chung, H. K., et al. (2016) · PubMed Central · Cited by 114
Yurdagul, A., Green, J., Albert, P., McInnis, M. C., Mazar, A. P., & Orr, A. W. (2014) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.114.303863 · Cited by 113
Self-citationMaladaptive regeneration - the reawakening of developmental pathways in NASH and fibrosis
Zhu, C., Tabas, I., Schwabe, R. F., & Pajvani, U. B. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00365-6 · Cited by 112 · cited 3×
“Hepatic fibrosis is largely mediated by the activation of non-parenchymal hepatic stellate cells that leads to their dedifferentiation towards a myofibroblast phenotype, enabling them to robustly synthesize and deposit ECM proteins (67).”
BackgroundInfluentialZhou, J., Pang, J., Tripathi, M., Ho, J. P., Widjaja, A. A., Shekeran, S. G., Cook, S. A., Suzuki, A., Diehl, A. M., Petretto, E. G., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32788-x · Cited by 112
Michiels, C. F., Kurdi, A., Timmermans, J., Meyer, G. R. Y. D., & Martinet, W. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.07.899 · Cited by 109
Ho, C., Ho, S., Jeng, Y., Lai, Y.-S., Chen, Y., Lu, S., Chen, H., Chang, P., Hu, R., & Lee, P. (2019) · Journal of Inflammation · doi:10.1186/s12950-019-0211-5 · Cited by 109
Rizzo, M., Chandalia, M., Patti, A. M., Di Bartolo, V., Rizvi, A. A., Montalto, G., & Abate, N. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-49 · Cited by 107
MacDonald, M. L. E., van Eck, M., Hildebrand, R. B., Wong, B. W. C., Bissada, N., Ruddle, P., Kontush, A., Hussein, H., Pouladi, M. A., Chapman, M. J., et al. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.181099 · Cited by 107
Schunk, S. J., Triem, S., Schmit, D., Zewinger, S., Sarakpi, T., Becker, E., Hütter, G., Wrublewsky, S., Küting, F., Hohl, M., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.053547 · Cited by 107
Smati, S., Polizzi, A., Fougerat, A., Ellero‐Simatos, S., Blum, Y., Lippi, Y., Régnier, M., Laroyenne, A., Huillet, M., Arif, M., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-323323 · Cited by 104
Mitchell, S. E., Delville, C., Konstantopedos, P., Hurst, J., Derous, D., Green, C., Chen, L., Han, J. J. D., Wang, Y., Promislow, D. E. L., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4003 · Cited by 103
Liu, J., Ren, Y., Kang, L., & Zhang, L. (2014) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2014.1681 · Cited by 103
Yang, R., Dong, J., Zhao, H., Li, H., Guo, H., Wang, S., Zhang, C., Wang, S., Wang, M., Yu, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099598 · Cited by 100
Barb, D., Bril, F., Kalavalapalli, S., & Cusi, K. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02414 · Cited by 100
Cui, G., Fan, Q., Li, Z., Goll, R., & Florholmen, J. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103329 · Cited by 100
Hasegawa, T., Iino, C., Endo, T., Mikami, K., Kimura, M., Sawada, N., Nakaji, S., & Fukuda, S. (2020) · Nutrients · doi:10.3390/nu12051450 · Cited by 99
Statins are associated with increased insulin resistance and secretion
Abbasi, F., Lamendola, C., Harris, C. S., Harris, V., Tsai, M.-S., Tripathi, P., Abbas, F., Reaven, G. M., Reaven, P. D., Snyder, M. P., et al. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.316159 · Cited by 98
Circulating Markers of Liver Function and Cardiovascular Disease Risk
Targher, G., & Byrne, C. D. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.305235 · Cited by 97
Bril, F., Portillo Sanchez, P., Lomonaco, R., Orsak, B., Hecht, J., Tio, F., & Cusi, K. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00867 · Cited by 97
Hyperinsulinemia and Atherosclerosis
Stout, R. W. (1996) · Diabetes · doi:10.2337/diab.45.3.s45 · Cited by 96
Grimaldi, P. A. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7278-5 · Cited by 95
Held, C., Hadziosmanovic, N., Aylward, P. E., Hagström, E., Hochman, J. S., Stewart, R. A. H., White, H. D., & Wallentin, L. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.023667 · Cited by 94
New Progress in Early Diagnosis of Atherosclerosis
Meng, H., Ruan, J., Yan, Z., Chen, Y., Liu, J., Li, X., & Meng, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168939 · Cited by 92 · cited 2×
“Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas.”
BackgroundZaric, B. L., Radovanovic, J. N., Gluvic, Z., Stewart, A. J., Essack, M., Motwalli, O., Gojobori, T., & Isenovic, E. R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.551758 · Cited by 91
Thompson, M., Saag, M., DeJesus, E., Gathe, J., Lalezari, J., Landay, A. L., Cade, J., Enejosa, J., Lefebvre, E., & Feinberg, J. (2016) · AIDS · doi:10.1097/qad.0000000000000988 · Cited by 88
Brocker, C. N., Patel, D. P., Velenosi, T. J., Kim, D., Yan, T., Yue, J., Li, G., Krausz, K. W., & Gonzalez, F. J. (2018) · Journal of Lipid Research · doi:10.1194/jlr.m088419 · Cited by 87
Liu, C., Schönke, M., Zhou, E., Li, Z., Kooijman, S., Boon, M. R., Larsson, M., Wallenius, K., Dekker, N., Barlind, L., et al. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab076 · Cited by 87
AMPK activation enhances the anti-atherogenic effects of high density lipoproteins in apoE−/− mice
Ma, A., Wang, J., Yang, L., An, Y., & Zhu, H. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m073270 · Cited by 86
Patel, M., Yarlagadda, V. K., Adedoyin, O. O., Saini, V., Assimos, D. G., Holmes, R. P., & Mitchell, T. (2017) · Redox Biology · doi:10.1016/j.redox.2017.12.003 · Cited by 85
Zelber‐Sagi, S., Wajcman, D. I., Isakov, N. F., Hahn, M., Webb, M., Shibolet, O., Kariv, R., & Tirosh, O. (2020) · Antioxidants · doi:10.3390/antiox9070578 · Cited by 84
Statins improve NASH via inhibition of RhoA and Ras
Schierwagen, R., Maybüchen, L., Hittatiya, K., Klein, S., Uschner, F. E., Braga, T. T., Franklin, B. S., Nickenig, G., Strassburg, C. P., Plat, J., et al. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00063.2016 · Cited by 81
Nikolic, D., Giglio, R. V., Rizvi, A. A., Patti, A. M., Montalto, G., Maranta, F., Cianflone, D., Stoian, A. P., & Rizzo, M. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00962-3 · Cited by 81
Kooistra, T., Verschuren, L., de Vries-van der Weij, J., Koenig, W., Toet, K., Princen, H. M. G., & Kleemann, R. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000238348.05028.14 · Cited by 78
Gluais‐Dagorn, P., Foretz, M., Steinberg, G. R., Batchuluun, B., Zawistowska‐Deniziak, A., Lambooij, J. M., Guigas, B., Carling, D., Monternier, P., Moller, D. E., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1799 · Cited by 77
Galvin, Z., Rajakumar, R., Chen, E., Adeyi, O., Selzner, M., Grant, D., Sapisochin, G., Greig, P., Cattral, M., McGilvray, I., et al. (2019) · Liver Transplantation · doi:10.1002/lt.25338 · Cited by 76
Cusi, K., Alkhouri, N., Harrison, S. A., Fouqueray, P., Moller, D. E., Hallakou-Bozec, S., Bolze, S., Grouin, J.-M., Jeannin Megnien, S., Dubourg, J., et al. (2021) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00300-9 · Cited by 75
Harrison, S. A., Manghi, F. P., Smith, W. B., Alpenidze, D., Aizenberg, D., Klarenbeek, N., Chen, C.-Y., Zuckerman, E., Ravussin, E., Charatcharoenwitthaya, P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01861-9 · Cited by 75
Iwao, M., Gotoh, K., Arakawa, M., Endo, M., Honda, K., Seike, M., Murakami, K., & Shibata, H. (2020) · Scientific Reports · doi:10.1038/s41598-020-75542-3 · Cited by 73
Treatment response in the PIVENS trial is associated with decreased Hedgehog pathway activity
Guy, C. D., Suzuki, A., Abdelmalek, M. F., Burchette, J. L., Diehl, A. M., & CRN, F. T. N. (2015) · Hepatology · doi:10.1002/hep.27235 · Cited by 72
Schwabl, P., Hambruch, E., Budas, G. R., Supper, P., Burnet, M., Liles, J. T., Birkel, M., Brusilovskaya, K., Königshofer, P., Peck-Radosavljevic, M., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9010060 · Cited by 70
Gianmoena, K., Gasparoni, N., Jashari, A., Gabrys, P., Grgas, K., Ghallab, A., Nordström, K. J. V., Gasparoni, G., Reinders, J., Edlund, K., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109526 · Cited by 69
Kawanaka, M., Nishino, K., Oka, T., Urata, N., Nakamura, J., Suehiro, M., Kawamoto, H., Chiba, Y., & Yamada, G. (2015) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s79100 · Cited by 68
Derosa, G., Cicero, A. F. G., D’Angelo, A., Gaddi, A. V., Ciccarelli, L., Piccinni, M. N., SALVADEO, S. A. T., PRICOLO, F., Ferrari, I., Gravina, A., et al. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.05.012 · Cited by 68
Grgurevic, I., Podrug, K., Mikolasevic, I., Kukla, M., Madir, A., & Tsochatzis, E. A. (2020) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2020/9181368 · Cited by 68
Gao, M., Zhao, W., Li, C., Xie, X., Li, M., Bi, Y., Fang, F., Du, Y., & Liu, X. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.09.078 · Cited by 67
Spontaneous atherosclerosis in the arterial system of ageing swine
Skold, B. H. (1962) · Iowa State University Digital Repository (Iowa State University) · doi:10.31274/rtd-180813-4328 · Cited by 65
The explosive growth of small voids in vulnerable cap rupture; cavitation and interfacial debonding
Maldonado, N., Kelly-Arnold, A., Cardoso, L., & Weinbaum, S. (2012) · Journal of Biomechanics · doi:10.1016/j.jbiomech.2012.10.040 · Cited by 65 · cited 2×
“Notably, this phenomenon is frequently observed in ruptured atheromas (45, 46).”
BackgroundOxalate: From the Environment to Kidney Stones
Brzica, H., Breljak, D., Burckhardt, B. C., Burckhardt, G., & Sabolić, I. (2013) · Archives of Industrial Hygiene and Toxicology · doi:10.2478/10004-1254-64-2013-2428 · Cited by 65
Lu, W., Mei, J., Yang, J., Wu, Z., Liu, J., Miao, P., Chen, Y., Wen, Z., Zhao, Z., Kong, H., et al. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117601 · Cited by 65
Chun, L., Junlin, Z., Aimin, W., Li, N., Benmei, C., & Minxiang, L. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.03.017 · Cited by 64
Yilmaz, Y., Yonal, O., Kurt, R., Ari, F., Oral, A. Y., Celikel, C. A., Korkmaz, S., Ulukaya, E., Ozdogan, O., Imeryuz, N., et al. (2010) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1258/acb.2010.010169 · Cited by 64
Rom, O., Korach-Rechtman, H., Hayek, T., Danin‐Poleg, Y., Bar, H., Kashi, Y., & Aviram, M. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1859-8 · Cited by 64
Self-citationInduction of glutathione biosynthesis by glycine-based treatment mitigates atherosclerosis
Rom, O., Liu, Y., Finney, A. C., Ghrayeb, A., Zhao, Y., Shukha, Y., Wang, L., Rajanayake, K. K., Das, S. R., Rashdan, N. A., et al. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102313 · Cited by 64
Self-citationMorrison, M. C., Mulder, P., Salic, K., Verheij, J., Liang, W., van Duyvenvoorde, W., Menke, A., Kooistra, T., Kleemann, R., & Wielinga, P. Y. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.74 · Cited by 63
Ceramides – Lipotoxic Inducers of Metabolic Disorders
Chaurasia, B., & Summers, S. A. (2017) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2017.09.005 · Cited by 63
Rom, O., Xu, G., Guo, Y., Zhu, Y., Wang, H. H., Zhang, J., Fan, Y., Liang, W., Lu, H., Liu, Y., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.02.019 · Cited by 63
Self-citationStepanova, M., Hossain, N., Afendy, A., Perry, K., Goodman, Z. D., Baranova, A. V., & Younossi, Z. M. (2010) · Obesity Surgery · doi:10.1007/s11695-010-0078-2 · Cited by 62
Yilmaz, Y., Ulukaya, E., Atug, O., & Dolar, E. (2009) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32832b77ae · Cited by 62
A small molecule targeting ALOX12-ACC1 ameliorates nonalcoholic steatohepatitis in mice and macaques
Zhang, X., Ji, Y., Cheng, X., Cheng, Y., Yang, H., Wang, J., Zhao, L., Huang, Y., Sun, D., Xiang, H., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abg8116 · Cited by 61
Increased serum concentration of ceramides in obese children with nonalcoholic fatty liver disease
Wasilewska, N., Bobrus‐Chociej, A., Harasim‐Symbor, E., Tarasów, E., Wojtkowska, M., Chabowski, A., & Lebensztejn, D. M. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0855-9 · Cited by 60
Ma, L., Ni, Y., Hu, L., Zhao, Y., Zheng, L., Yang, S., Ni, L., & Fu, Z. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118739 · Cited by 59
Jauhiainen, R., Vangipurapu, J., Laakso, A., Kuulasmaa, T., Kuusisto, J., & Laakso, M. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab562 · Cited by 59
Sutanto, A., Wungu, C. D. K., Susilo, H., & Sutanto, H. (2021) · Nutrients · doi:10.3390/nu13103568 · Cited by 59
Romeo, S., Yin, W., Kozlitina, J., Pennacchio, L. A., Boerwinkle, E., Hobbs, H. H., & Cohen, J. C. (2008) · Journal of Clinical Investigation · doi:10.1172/jci37118 · Cited by 58
Morrison, M. C., Verschuren, L., Salic, K., Verheij, J., Menke, A., Wielinga, P. Y., Iruarrizaga‐Lejarreta, M., Gole, L., Yu, W., Turner, S., et al. (2018) · Hepatology Communications · doi:10.1002/hep4.1270 · Cited by 58 · cited 15×
“In a phase IIa trial including individuals with hepatic steatosis and fibrosis, treatment for 12 weeks with a FAS inhibitor, TVB-2640, dose-dependently decreased circulating ALT, AST and liver fat determined by MRI-PDFF.”
BackgroundInfluentialCholesterol metabolism in rhesus monkey, squirrel monkey, and baboon
Eggen, D. A. (1974) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)36816-4 · Cited by 56
Wang, X., Sommerfeld, M. R., Jahn‐Hofmann, K., Cai, B., Filliol, A., Remotti, H. E., Schwabe, R. F., Kannt, A., & Tabas, I. (2019) · Hepatology Communications · doi:10.1002/hep4.1405 · Cited by 56
Self-citationLawitz, E., Bhandari, B. R., Ruane, P. J., Kohli, A., Harting, E., Ding, D., Chuang, J.-C., Huss, R. S., Chung, C., Myers, R. P., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.12.044 · Cited by 56
Divergent effects of glucose and fructose on hepatic lipogenesis and insulin signaling
Softic, S., Gupta, M. K., Wang, G.-X., Fujisaka, S., O'Neill, B. T., Rao, T. N., Willoughby, J. L. S., Harbison, C. E., Fitzgerald, K. J., Ilkayeva, O., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99009 · Cited by 56 · cited 5×
“In a phase IIa trial including individuals with hepatic steatosis and fibrosis, treatment for 12 weeks with a FAS inhibitor, TVB-2640, dose-dependently decreased circulating ALT, AST and liver fat determined by MRI-PDFF.”
BackgroundInfluentialChen, H., Li, D., Saldeen, T., & Mehta, J. L. (2001) · Circulation Research · doi:10.1161/hh2401.100598 · Cited by 55
Chiba, T., Suzuki, S., Sato, Y., Itoh, T., & Umegaki, K. (2016) · PLOS ONE · doi:10.1371/journal.pone.0164191 · Cited by 55 · cited 3×
“Choline and methionine deficiency diminishes VLDL assembly and reduces triglyceride clearance but results in weight loss (113), contrasting with typical weight gain associated with most human NASH.”
BackgroundInfluentialInsights into the Role of PPARβ/δ in NAFLD
Chen, J., Montagner, A., Tan, N. S., & Wahli, W. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071893 · Cited by 55
Morinaga, J., Zhao, J., Endo, M., Kadomatsu, T., Miyata, K., Sugizaki, T., Okadome, Y., Tian, Z., Horiguchi, H., Miyashita, K., et al. (2018) · PLOS ONE · doi:10.1371/journal.pone.0193731 · Cited by 54
The genetic interactions between non-alcoholic fatty liver disease and cardiovascular diseases
Chew, N., Chong, B., Ng, C. H., Kong, G., Chin, Y. H., Xiao, W., Lee, C. J. M., Dan, Y. Y., Muthiah, M. D., & Foo, R. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.971484 · Cited by 53 · cited 1×
“Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas.”
BackgroundMeeusen, J. W., Donato, L. J., Kopecky, S. L., Vasile, V. C., Jaffe, A. S., & Laaksonen, R. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.10.005 · Cited by 52
Doğru, T., Kırık, A., Gürel, H., Rizvi, A. A., Rizzo, M., & Sönmez, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126627 · Cited by 52
Dysregulated oxalate metabolism is a driver and therapeutic target in atherosclerosis
Liu, Y., Zhao, Y., Shukha, Y., Lu, H., Wang, L., Liu, Z., Liu, C., Zhao, Y., Wang, H. H., Zhao, G., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109420 · Cited by 52
Self-citationMetabolomic Profiling Reveals a Role for Caspase-2 in Lipoapoptosis
Johnson, E. S., Lindblom, K., Robeson, A. C., Stevens, R. D., Ilkayeva, O., Newgard, C. B., Kornbluth, S. A., & Andersen, J. L. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.437210 · Cited by 50 · cited 1×
“Consequently, Jun N-terminal kinase (JNK) becomes activated and promotes intrinsic apoptosis through a caspase-2-BID signaling pathway (55).”
BackgroundLeucine supplementation via drinking water reduces atherosclerotic lesions in apoE null mice
Zhao, Y., Dai, X.-Y., Zhou, Z., Zhao, G., Wang, X., & Xu, M. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2015.88 · Cited by 50
Wu, G., Li, H., Fang, Q., Zhang, J., Zhang, M., Zhang, L., Wu, L., Hou, X., Lu, J., Bao, Y., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-05257-5 · Cited by 49
A Human-Type Nonalcoholic Steatohepatitis Model with Advanced Fibrosis in Rabbits
Ogawa, T., Fujii, H., Yoshizato, K., & Kawada, N. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090895 · Cited by 48
Rom, O., Grajeda‐Iglesias, C., Najjar, M., Abu‐Saleh, N., Volkova, N., Dar, D. E., Hayek, T., & Aviram, M. (2017) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2017.02.023 · Cited by 48
Self-citationWu, L., Qian, L., Zhang, L., Zhang, J., Zhou, J., Li, Y., Hou, X., Fang, Q., Li, H., & Jia, W. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015226 · Cited by 48
van den Hoek, A. M., Verschuren, L., Worms, N., van Nieuwkoop, A., de Ruiter, C., Attema, J., Menke, A. L., Caspers, M. P. M., Radhakrishnan, S., Salic, K., et al. (2020) · Cells · doi:10.3390/cells9092014 · Cited by 48
Pfau, A., Ermer, T., Coca, S. G., Tio, M. C., Genser, B., Reichel, M., Finkelstein, F. O., März, W., Wanner, C., Waikar, S. S., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020121793 · Cited by 48
Higgins, P. B., Bastarrachea, R. A., López-Alvarenga, J. C., Garcia-Forey, M., Proffitt, J. M., Voruganti, V. S., Tejero, M. E., Mattern, V. L., Haack, K., Shade, R. E., et al. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-71 · Cited by 47
de Mello, V. D., Sehgal, R., Männistö, V., Klåvus, A., Nilsson, E., Perfilyev, A., Kamińska, D., Miao, Z., Pajukanta, P., Ling, C., et al. (2020) · Liver International · doi:10.1111/liv.14743 · Cited by 46
Yokohama, K., Fukunishi, S., Ii, M., Nakamura, K., Ohama, H., Tsuchimoto, Y., Asai, A., Tsuda, Y., & Higuchi, K. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2766 · Cited by 45
Cazac, G.-D., Lăcătușu, C.-M., Mihai, C., Grigorescu, E.-D., Onofriescu, A., & Mihai, B. M. (2022) · Life · doi:10.3390/life12081189 · Cited by 45
Karavia, E. A., Papachristou, D. J., Kotsikogianni, I., Giopanou, I., & Kypreos, K. E. (2011) · The FEBS Journal · doi:10.1111/j.1742-4658.2011.08238.x · Cited by 44 · cited 2×
“2% cholesterol (86, 91), Schierwagen et al.”
BackgroundKarami, S., Poustchi, H., Sarmadi, N., Radmard, A. R., Yari, F. A., Pakdel, A., & Shabani, P. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00741-5 · Cited by 44
Distinguishing NASH Histological Severity Using a Multiplatform Metabolomics Approach
Ioannou, G. N., Gowda, G. A. N., Djukovic, D., & Raftery, D. (2020) · Metabolites · doi:10.3390/metabo10040168 · Cited by 43
Akhiyat, N., Vasile, V. C., Ahmad, A., Sara, J. D. S., Nardi, V., Lerman, L. O., Jaffe, A. S., & Lerman, A. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.022852 · Cited by 43
Association of serum glycine levels with metabolic syndrome in an elderly Chinese population
Li, X., Sun, L., Zhang, W., Li, H., Wang, S., Mu, H., Zhou, Q., Zhang, Y., Tang, Y., Wang, Y., et al. (2018) · Nutrition & Metabolism · doi:10.1186/s12986-018-0325-4 · Cited by 41
Lee, M. K. S., Cooney, O. D., Lin, X., Nadarajah, S., Dragoljevic, D., Huynh, K., Onda, D.-A., Galić, S., Meikle, P. J., Edlund, H., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101514 · Cited by 41
Nonalcoholic fatty liver disease in inflammatory arthritis: Relationship with cardiovascular risk
Barbarroja, N., Ruiz-Ponce, M., Cuesta-López, L., Pérez‐Sánchez, C., López-Pedrera, C., de la Rosa, I. A., & Collantes‐Estévez, E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.997270 · Cited by 41
Impact of NAFLD and its pharmacotherapy on lipid profile and CVD
Wang, Z., Ye, M., Zhang, X., Zhang, P., Cai, J., Li, H., & She, Z. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.07.010 · Cited by 40
Chen, X., Zhang, Y., Chen, Q., Li, Q., Li, Y., & Ling, W. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309700 · Cited by 38
Zhou, M., Learned, R. M., Rossi, S. J., Tian, H., DePaoli, A. M., & Ling, L. (2019) · Journal of Lipid Research · doi:10.1194/jlr.m089961 · Cited by 38
Research works printed but not linked: 2
- Linton, 2000, The role of lipids and lipoproteins in atherosclerosis, 1
- Ignatowski, 1908, Influence of animal food on the organsim of rabbits, Izvest Imper Voennomed Akad St Petersburg, 16, 154
Cited by
Zheng, H., Sechi, L. A., Navarese, E. P., Casu, G., & Vidili, G. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02434-5 · Cited by 185
“Elevated TG levels are associated with an increased risk of CVD, as they can directly and indirectly contribute to atherosclerosis by forming sdLDL particles that are particularly atherogenic [83].”
BackgroundAmino Acid Metabolism and Atherosclerotic Cardiovascular Disease
Anand, S. K., Governale, T.-A., Zhang, X., Razani, B., Yurdagul, A., Pattillo, C. B., & Rom, O. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2023.12.006 · Cited by 55
Self-citationWhat are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
Tarantino, G., & Citro, V. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02031-1 · Cited by 40
“There are conflicting results related to the role of SIRT4 in the development of atherosclerosis, which is strongly associated with NAFLD [144] and heavy alcohol consumption [145].”
BackgroundMetabolomics at the cutting edge of risk prediction of MASLD
Tan, E. Y., Muthiah, M. D., & Sanyal, A. J. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101853 · Cited by 50
“5,54 Interestingly, certain genetic polymorphisms such as in PNPLA3 and TM6SF2 favor MASLD development but are associated with a lower-risk lipoprotein profile 55 ; these are discussed later in this review.”
EHBP1 suppresses liver fibrosis in metabolic dysfunction-associated steatohepatitis
Ma, F., Longo, M., Meroni, M., Bhattacharya, D., Paolini, E., Mughal, S., Hussain, S., Anand, S. K., Gupta, N., Zhu, Y., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.01.020 · Cited by 29
Self-citation
Metadata
- Authors
- Finney, A. C., Das, S., Kumar, D., McKinney, M. P., Cai, B., Yurdagul, A., & Rom, O.
- Affiliations
- Louisiana State University (US)
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Yurdagul, Arif
- Rom, Oren
- ORCID
- Venue
- Frontiers in Cardiovascular Medicine
- Publisher
- Frontiers Media SA
- Published
- 2023-05-02
- Volume
- 10
- Pages
- 1116861-1116861
- ISSN
- 2297-055X (ISSN-L)
- PMC
- PMC10185914
- OpenAlex
- W4367678781
- Cited by
- 40
- References
- 448
- Citations by year
- 2026: 9 · 2025: 11 · 2024: 16 · 2023: 4
- FWCI
- 1.56
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Cardiovascular Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (DK134011, HL150233, HL145131, DK115778, GM147269)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, atherosclerotic cardiovascular disease, dyslipidemia, LDL cholesterol lowering, obesity, disease pathophysiology, atherogenic dyslipidemia, biomarkers, disease modeling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.